BCG
TRDA icon

BayBridge Capital Group’s Entrada Therapeutics TRDA Stock Holding History

BayBridge Capital Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,563
Closed -$494K – 115
2024
Q4 		$494K Sell
28,563
-476
-2% -$8.62K 0.36% 66
2024
Q3 		$464K Buy
+29,039
New +$458K 0.33% 73

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BayBridge Capital Group's TRDA Position: Q1 2025 in Review

BayBridge Capital Group sold out of Entrada Therapeutics (TRDA) in Q1 2025, closing a stake of 28,563 shares — an estimated $494K sold.

BayBridge Capital Group first reported a position in TRDA in Q3 2024 and held it in 2 quarters. The position peaked at $494K in Q4 2024. 111 funds tracked by Wall St. Rank hold TRDA as of Q1 2025.

  • BayBridge Capital Group reported no remaining Entrada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BayBridge Capital Group sold 28,563 Entrada Therapeutics shares in Q1 2025, an estimated $494K.
  • BayBridge Capital Group first reported a position in Entrada Therapeutics in Q3 2024 and held it in 2 quarters.
  • BayBridge Capital Group's Entrada Therapeutics position peaked at $494K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2025.

Based on BayBridge Capital Group's 13F filing for Q1 2025, filed 17 Apr 2025.